Results 21 to 30 of about 313,411 (354)
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]
Pharmacological Reviews, 2017 The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Stefan Prost +4 more
openaire +2 more sources
JCI Insight, 2022 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
A. Merleev +19 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2022 Chronic liver diseases are commonly associated with dysregulated cholesterol metabolism. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease of the proprotein convertase family that is mainly synthetized and secreted by the liver ...
T. Grewal, C. Buechler
semanticscholar +1 more source
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]
Clinical Research in Cardiology Supplements, 2019 Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles.
Julius, U +4 more
openaire +3 more sources
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [PDF]
Canadian Medical Association Journal, 2019 PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled ...
Derek Leong, Peter E. Wu
openaire +3 more sources
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study [PDF]
Cardiovascular Diabetology, 2020 Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by targeting the low-density lipoprotein receptor.
Jie Shi +11 more
openalex +2 more sources
Antioxidants, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly secreted in the liver, is a key regulator of cholesterol homeostasis inducing LDL receptors’ degradation.
V. Cammisotto +8 more
semanticscholar +1 more source
American Journal of Medical Genetics Part A, Volume 191, Issue 1, Page 228-233, January 2023., 2023 Abstract Pulmonary arterial hypertension (PAH) is a disease characterized by pathological remodeling of the pulmonary vasculature causing elevated pulmonary artery pressures and ultimately, right ventricular failure from chronic pressure overload. Heterozygous pathogenic GDF2 (encoding bone morphogenetic protein 9 (BMP9)) variants account for some (>1%)
Paul Upton +5 more
wiley +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li +3 more
doaj +1 more source